Claims for Patent: 6,255,054

Summary for Patent: 6,255,054

Title:	Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
Abstract:	The present invention concerns a method and kit for determining if a subject is at increased or decreased risk of developing Alzheimer\'s disease. The invention further concerns vectors, transformed cells or transgenic mammals which can be used in a method for the screening of compound capable of modulating the expression of the GluR-5 gene or the activity of the GluR-5 receptor. The compounds selected by the method of the invention, as medicament for the treatment or the prevention of Alzheimer\'s disease, also form part of the present invention.
Inventor(s):	Hugon; Jacques (87000 Limoges, FR), Baclet; Marie-Claire (87000 Limoges, FR)
Assignee:
Application Number:	09/392,486
Patent Claims:	1. A method for determining if a subject is at increased or decreased risk of developing a sporadic form of Alzheimer's disease comprising the steps of: a) collecting a biological sample containing genomic DNA from the subject; b) determining the tetranucleotide AGAT repeats number present in an intronic polynucleotide of the gene GluR-5 which is amplified by polymerase chain reaction with the primers having the sequences SEQ ID No: 1 and SEQ ID No: 2, on each allele; c) calculating the total number of tetranucleotide AGAT repeats by adding the tetranucleotide AGAT repeats number determined for each allele in step b); d) observing whether or not the subject is at increased or decreased risk of developing Alzheimer's disease by observing the total number of tetranucleotide AGAT repeats determined in step c) wherein a total number of AGAT repeats equal or superior to 18 indicates said subject is at increased risk of developing said sporadic form of Alzheimer's disease and wherein a total number of AGAT repeats inferior to 18 indicates said subject is at decreased risk of developing said sporadic form of Alzheimer's disease, in the case said subject is known not to be affected by the Down syndrome. 2. A method according to claim 1, wherein the genomic DNA of step a) is isolated from venous blood lymphocytes. 3. A method according to claim 1, characterized in that step b) comprises the amplification of the intronic polynucleotide of the gene GluR-5 which can be amplified by polymerase chain reaction with the primers having the sequences SEQ ID No: 1 and SEQ ID No: 2. 4. A method according to claim 1, characterized in that step b) comprises a step of amplification wherein said intronic polynucleotide of the gene GluR-5 containing the tetranucleotide AGAT repeats is specifically amplified by polymerase chain reaction with the primers having the sequences SEQ ID No: 1 and SEQ ID No: 2. 5. A method according to claim 1, wherein the tetranucleotide AGAT repeats number present in the intronic polynucleotide of the gene GluR-5 on each different allele is obtained in step b) by determining the size of and/or sequencing the amplified products obtained after polymerase chain reaction. 6. A method according to claim 1, characterized in that said method further comprises assaying a biological sample from said subject for levels of at least an additional marker associated with the increased risk of developing said sporadic form of Alzheimer's disease, the presence of a significantly level of said at least one marker allowing to confirm if said subject is at increased risk of developing said sporadic form of Alzheimer's disease. 7. A method according to claim 6, characterized in that said second method comprises the following steps of: (i) detecting the presence or absence of an ApoE4 isoform in a biological sample of said subject by using at least one reagent that specifically detects apolipoprotein E type 4 (ApoE4), wherein said reagent is selected from the group consisting of antibodies that selectively bind ApoE4, and oligonucleotide probes that selectively bind to DNA encoding ApoE4; and (ii) observing if the presence of ApoE4 is or is not detected with said at least one reagent wherein the presence of ApoE4 confirms said subject is at increased risk of developing Alzheimer's disease. 8. A method according to claim 6, characterized in that said at least additional marker associated is selected from the group of markers consisting of bleomycin hydrolase gene polymorphism, FE65 protein gene polymorphism, polymorphic tetranucleotide ATTT repeat site within the intron 7 of the beta-amyloid precursor protein gene and the persyn (gamma-synuclein) gene polymorphism.

Details for Patent 6,255,054

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26